Praeruptorin A: Multi-Targeted Angular Pyranocoumarin for Inflammation and Cancer Biology

Executive Summary: Praeruptorin A is a bioactive angular pyranocoumarin compound extracted from Peucedanum praeruptorum Dunn. It inhibits DMT1-mediated ferroptosis, STAT-1/3 phosphorylation, and NF-κB pathway activation, reducing inflammatory cytokines and enhancing epithelial barrier proteins. In vivo, it alleviates DSS-induced ulcerative colitis in mice and inhibits migration of hepatocellular carcinoma cells, with minimal cytotoxicity and no significant multi-organ toxicity at effective doses (Xiao et al. 2025). Praeruptorin A is available from APExBIO, with precise storage and solubility parameters for laboratory use (APExBIO).

Biological Rationale

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by mucosal inflammation and epithelial disruption, leading to abdominal pain, diarrhea, and rectal bleeding (Xiao et al. 2025). Conventional therapies such as corticosteroids and immunosuppressants can cause adverse effects and frequent relapse. There is growing interest in natural compounds with multi-targeted biological activities to address inflammation, barrier repair, and cancer metastasis. Praeruptorin A, obtained from the roots of Peucedanum praeruptorum Dunn, is one such candidate, exhibiting anti-inflammatory, antitumor, and organ-protective actions (APExBIO).

Mechanism of Action of Praeruptorin A

• Praeruptorin A inhibits divalent metal transporter 1 (DMT1), suppressing cellular Fe²⁺ overload and downstream ferroptosis in oxidative environments (see review).
• It blocks phosphorylation of STAT-1 and STAT-3 proteins, thereby reducing pro-inflammatory cytokine transcription and immune cell recruitment (Xiao et al. 2025).
• Praeruptorin A downregulates activation of AKT, p65, and p38, further suppressing NF-κB pathway activity and the expression of IL-1β, TNF-α, and PTGS2 (COX-2) (APExBIO).
• It restores intestinal barrier function by upregulating tight junction proteins (ZO-1, occludin, claudin-1), limiting paracellular permeability in UC models (Xiao et al. 2025).
• In hepatocellular carcinoma models, Praeruptorin A downregulates MMP1 via ERK1/2 signaling, reducing cell migration and invasion (see mechanistic guidance).

Evidence & Benchmarks

• Praeruptorin A (PA) at 0.4–75 μM in vitro reduces pro-inflammatory cytokine (TNF-α, IL-6, IL-1β) levels and increases anti-inflammatory markers (IL-10, TGF-β) in Caco-2 cells and DSS-induced mouse models (Xiao et al. 2025).
• In vivo, PA administered at 0.8–1.2 mg/kg/day intraperitoneally or 30 mg/kg/day intragastrically alleviates colonic inflammation, reduces apoptosis (caspase-3 activation), and restores tight junction protein expression in DSS-induced colitis mice (Xiao et al. 2025).
• PA suppresses NF-κB pathway activation and downregulates PTGS2 and HMOX1 expression, confirmed by Western blot and qPCR in both cell and animal models (APExBIO).
• Hepatocellular carcinoma cell migration and invasion are reduced through MMP1 downregulation via ERK1/2 pathway targeting (in vitro, 10–50 μM PA) (see strategic guidance).
• No significant cytotoxicity or organ toxicity observed in mice at effective PA doses; safety validated via histopathology and serum markers (Xiao et al. 2025).

Applications, Limits & Misconceptions

Therapeutic and Research Applications

• Anti-inflammatory agent for ulcerative colitis: PA demonstrated histological and symptomatic improvement in DSS-induced mouse models (Xiao et al. 2025).
• Ferroptosis inhibitor in oxidative stress and cardiomyopathy research, via DMT1 suppression (see review).
• Hepatocellular carcinoma metastasis inhibitor: Limits cell migration and invasion through ERK1/2 and MMP1 modulation (see mechanistic innovation).
• Adjuvant in doxorubicin-based chemotherapy: Synergistically enhances antitumor effects while protecting against cardiotoxicity (APExBIO).

This article extends the mechanistic focus presented in 'Praeruptorin A: Mechanistic Innovation and Strategic Guidance' by providing quantitative benchmarks and recent peer-reviewed validation. It also updates 'Praeruptorin A: Multifunctional Inhibitor for Cardiac and Cancer Biology' by reporting in vivo safety and effective dose ranges.

Common Pitfalls or Misconceptions

• Water solubility is negligible: PA is insoluble in water; use DMSO (≥50.8 mg/mL) or ethanol (≥12.68 mg/mL with ultrasonic treatment) for preparation (APExBIO).
• Not a pan-inhibitor: Efficacy is specific to targets such as DMT1, STAT-1/3, and NF-κB; it does not broadly suppress all inflammatory pathways.
• Limited CNS penetration: Data on blood-brain barrier permeability are lacking; PA is not validated for neuroinflammatory disorders.
• Not a replacement for standard UC therapy: PA is investigational and not approved as a primary UC treatment in humans (Xiao et al. 2025).
• Storage sensitivity: PA solution stability declines with light or prolonged storage; always keep at 4°C protected from light (APExBIO).

Workflow Integration & Parameters

• Preparation: Dissolve PA in DMSO or ethanol; avoid water. For in vitro, filter-sterilize and dilute to 0.4–75 μM as per cell line sensitivity.
• In vivo dosing: Intraperitoneal: 0.8–1.2 mg/kg/day; intragastric: 30 mg/kg/day (mouse models). Confirm dose-response in pilot studies.
• Storage: Store dry powder at 4°C away from light. Avoid repeated freeze-thaw cycles and prolonged solution storage.
• Controls: Always compare to vehicle-treated and positive control groups (e.g., AG490 for STAT-1/3 inhibition).
• Availability: Order as product N2885 from APExBIO.

Conclusion & Outlook

Praeruptorin A is a validated multi-targeted inhibitor with specific activity against DMT1, STAT-1/3, and NF-κB signaling. It offers reproducible efficacy in preclinical inflammation and cancer models with defined safety windows. Future research should focus on translational studies, human pharmacokinetics, and clinical trial validation. For bench-to-clinic workflows, detailed protocols and safety data are available from APExBIO (product page).